NexImmune, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 32.34 million compared to USD 62.51 million a year ago. Basic loss per share from continuing operations was USD 30.82 compared to USD 64.95 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.375 USD | +2.90% | -1.60% | +52.03% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+52.03% | 4.5M | |
-3.14% | 102B | |
+1.77% | 96.29B | |
+2.13% | 22.18B | |
-15.61% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-15.24% | 16.36B | |
+5.15% | 13.97B | |
+33.26% | 12.17B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023